Published in Zhonghua Yi Xue Za Zhi on April 01, 1998
The spatial organization of human chromosomes within the nuclei of normal and emerin-mutant cells. Hum Mol Genet (2001) 4.79
A focused ultrasoft x-ray microbeam for targeting cells individually with submicrometer accuracy. Radiat Res (2001) 1.25
Inactivated poliovirus vaccine: past and present experience. Vaccine (1996) 1.22
Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen- to nineteen-month-old infants. J Pediatr (1997) 1.10
Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of age. Pediatr Infect Dis J (1994) 1.07
An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine (2000) 1.05
Adverse reactions to the preschool (fifth) dose of adsorbed diphtheria-pertussis-tetanus vaccine in Canadian children. CMAJ (1991) 1.04
Plasma-lymph exchange and interstitial distribution volumes of charged macromolecules in the lung. J Appl Physiol (1985) (1985) 1.00
Measles vaccination of infants in a well-vaccinated population. Pediatr Infect Dis J (1995) 0.97
Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine (2012) 0.93
Vietnamese women and Pap smears: issues in promotion. Aust N Z J Public Health (1999) 0.91
Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect Dis J (2000) 0.85
Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid? CMAJ (1993) 0.83
Evaluation of booster doses of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in 18-month-old children. Vaccine (1995) 0.83
Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria. Clin Exp Immunol (1991) 0.81
Cell-mediated and antibody immune responses to AIK-C and Connaught monovalent measles vaccine given to 6 month old infants. Vaccine (1999) 0.81
Homosexual rape and sexual selection in acanthocephalan worms. Science (1977) 0.81
Post-marketing surveillance of adverse events following ProHIBit vaccine--British Columbia. Can Dis Wkly Rep (1989) 0.80
Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age. Pediatr Infect Dis J (1999) 0.80
Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine (1996) 0.79
[Quality evaluation of primary health care in an urban area of southern Brazil]. Rev Saude Publica (1994) 0.78
Pharmacokinetics of meloxicam in koalas (Phascolarctos cinereus) after intravenous, subcutaneous and oral administration. J Vet Pharmacol Ther (2013) 0.77
Immunogenicity of a five-component acellular pertussis vaccine in infants and young children. Arch Pediatr Adolesc Med (1994) 0.77
Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old. Scand J Infect Dis (1995) 0.77
Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Dev Biol Stand (1998) 0.77
Safety and immunogenicity of an acellular pertussis diphtheria tetanus vaccine given as a single injection with Haemophilus influenzae b conjugate vaccine. Vaccine (1997) 0.76
Controlled study of a new five-component acellular pertussis vaccine in adults and young children. J Infect Dis (1992) 0.76
Placental protein tyrosine nitration and MAPK in type 1 diabetic pre-eclampsia: Impact of antioxidant vitamin supplementation. J Diabetes Complications (2013) 0.76
Safety and immunogenicity of a five-component acellular pertussis vaccine with varying antigen quantities. Arch Pediatr Adolesc Med (1994) 0.76
Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J (1995) 0.76
Extended follow-up of antibody levels and antigen responsiveness after 2 Haemophilus influenzae type b conjugate vaccines. J Pediatr (1999) 0.76
Standardization of BCG multiple puncture 40 mg and BCG live (intravesical) Theracys/BCG therapeutic Immucyst. Dev Biol Stand (1992) 0.75
The launch of an infant Haemophilus influenzae type B immunization programme in Iceland. Arctic Med Res (1991) 0.75
Stability of BCG vaccine (intravesical) Theracys/BCG therapeutic ImmuCyst and its importance in clinical efficacy. Dev Biol Stand (1992) 0.75
Reversible zidovudine-induced pure red cell aplasia. AIDS (1999) 0.75
Failure of myocardial ischemia to increase pulmonary microvascular permeability in dogs. J Appl Physiol Respir Environ Exerc Physiol (1984) 0.75
Comparison of alpha 1-adrenergic receptor-stimulated inositol phosphate formation in primary neuronal and glial cultures. J Neurochem (1990) 0.75
Interesting case: an unusual case of oral ulceration. Br J Oral Maxillofac Surg (2005) 0.75
Smokeless tobacco: a northern perspective. Can Nurse (1987) 0.75